首页 > 最新文献

World Journal of Surgical Oncology最新文献

英文 中文
Alteration of the immune microenvironment in the axillary metastatic lymph nodes of luminal A breast cancer patients. 腔隙性 A 型乳腺癌患者腋窝转移淋巴结免疫微环境的改变。
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2024-06-27 DOI: 10.1186/s12957-024-03454-x
Min Wu, Shuo Wang, Keyu Yuan, Bingjun Xiong, Yanping Li, Shuzhen Lyu

Background: The alteration of the immune microenvironment in the axillary metastatic lymph nodes of luminal A breast cancer patients is still unclear.

Methods: Postsurgical tissues from the enrolled luminal A BCs were divided into five categories: primary BC lesion at stage N0 (PL1), primary BC lesion at stage N1 (PL2), negative axillary lymph node at stage N0 BC (LN1), negative axillary lymph node at stage N1 BC (LN2), and positive axillary lymph node at stage N1 BC (LN3). The frequencies of positive immune markers (CD4, CD8, PD1, PD-L1, T-cell immunoglobulin and mucin domain 3 (TIM3), and forkhead box protein 3 (Foxp3)) in the above tissues were quantified by AKOYA Opal Polaris 7 Color Manual IHC Detection Kit.

Results: A total of 50 female patients with luminal A BC were enrolled in this study. Among these patients, 23 had stage N1 disease, and 27 had stage N0 disease. Compared with that in the PL2 subgroup, the frequency of PD-1-positive cells was significantly greater in the PL1 subgroup, whether at the stromal or intratumoral level (P value < 0.05). Both the frequency of CD8 + T cells in LN1 and that in LN2 were significantly greater than that in LN3 (P value < 0.05). The frequency of TIM3 + T cells in LN1 was significantly greater than that in PL1 (P value < 0.05). The frequency of CD8 + TIM3 + T cells was significantly greater in both the LN2 and LN3 groups than in the PL2 group (P value < 0.05). The frequency of CD4 + Foxp3 + T cells was significantly greater in LN1 than in PL1 (P value < 0.05), which was the same for both LN3 and PL2 (P value < 0.05).

Conclusion: Increased frequencies of CD8 + PD1+, CD8 + TIM3 + and CD4 + Foxp3 + T cells might inhibit the immune microenvironment of axillary metastatic lymph nodes in luminal A breast cancer patients and subsequently promote lymph node metastasis.

背景腔隙性A型乳腺癌患者腋窝转移淋巴结免疫微环境的改变尚不清楚:将入选的管腔A型乳腺癌患者的术后组织分为五类:N0期原发病灶(PL1)、N1期原发病灶(PL2)、N0期腋窝淋巴结阴性(LN1)、N1期腋窝淋巴结阴性(LN2)和N1期腋窝淋巴结阳性(LN3)。采用 AKOYA Opal Polaris 7 彩色手动 IHC 检测试剂盒对上述组织中的阳性免疫标记物(CD4、CD8、PD1、PD-L1、T 细胞免疫球蛋白和粘蛋白结构域 3 (TIM3)、叉头盒蛋白 3 (Foxp3))的频率进行量化:本研究共纳入50例女性管腔A型BC患者。其中,23 例为 N1 期,27 例为 N0 期。与PL2亚组相比,PL1亚组中PD-1阳性细胞的频率明显更高,无论是在基质水平还是在瘤内水平(P值 结论:PD-1阳性细胞的频率在PL1亚组中明显高于PL2亚组:CD8 + PD1+、CD8 + TIM3 + 和 CD4 + Foxp3 + T 细胞频率的增加可能会抑制管腔 A 型乳腺癌患者腋窝转移淋巴结的免疫微环境,进而促进淋巴结转移。
{"title":"Alteration of the immune microenvironment in the axillary metastatic lymph nodes of luminal A breast cancer patients.","authors":"Min Wu, Shuo Wang, Keyu Yuan, Bingjun Xiong, Yanping Li, Shuzhen Lyu","doi":"10.1186/s12957-024-03454-x","DOIUrl":"https://doi.org/10.1186/s12957-024-03454-x","url":null,"abstract":"<p><strong>Background: </strong>The alteration of the immune microenvironment in the axillary metastatic lymph nodes of luminal A breast cancer patients is still unclear.</p><p><strong>Methods: </strong>Postsurgical tissues from the enrolled luminal A BCs were divided into five categories: primary BC lesion at stage N0 (PL1), primary BC lesion at stage N1 (PL2), negative axillary lymph node at stage N0 BC (LN1), negative axillary lymph node at stage N1 BC (LN2), and positive axillary lymph node at stage N1 BC (LN3). The frequencies of positive immune markers (CD4, CD8, PD1, PD-L1, T-cell immunoglobulin and mucin domain 3 (TIM3), and forkhead box protein 3 (Foxp3)) in the above tissues were quantified by AKOYA Opal Polaris 7 Color Manual IHC Detection Kit.</p><p><strong>Results: </strong>A total of 50 female patients with luminal A BC were enrolled in this study. Among these patients, 23 had stage N1 disease, and 27 had stage N0 disease. Compared with that in the PL2 subgroup, the frequency of PD-1-positive cells was significantly greater in the PL1 subgroup, whether at the stromal or intratumoral level (P value < 0.05). Both the frequency of CD8 + T cells in LN1 and that in LN2 were significantly greater than that in LN3 (P value < 0.05). The frequency of TIM3 + T cells in LN1 was significantly greater than that in PL1 (P value < 0.05). The frequency of CD8 + TIM3 + T cells was significantly greater in both the LN2 and LN3 groups than in the PL2 group (P value < 0.05). The frequency of CD4 + Foxp3 + T cells was significantly greater in LN1 than in PL1 (P value < 0.05), which was the same for both LN3 and PL2 (P value < 0.05).</p><p><strong>Conclusion: </strong>Increased frequencies of CD8 + PD1+, CD8 + TIM3 + and CD4 + Foxp3 + T cells might inhibit the immune microenvironment of axillary metastatic lymph nodes in luminal A breast cancer patients and subsequently promote lymph node metastasis.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11210032/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141471116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A controlled study of the hygienic technical evaluation of the transaxillary approach for inflation-free single-port lumpectomy versus conventional transcervical anterior open surgery in radical thyroid cancer resection. 甲状腺癌根治术中经腋窝无充气单孔肿物切除术与传统经颈椎前路开放手术的卫生技术评估对照研究。
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2024-06-27 DOI: 10.1186/s12957-024-03445-y
Jie Chen, Bo Xu Bm, Chaojie Zhang Bm, Chengquan Ma, Tianwen Lu

Objective: To evaluate sanitary techniques for radical thyroid cancer surgery via the transaxillary approach without inflation single-port endoscopic surgery (TAWISES) and the conventional open anterior cervical approach (COACAS) in a controlled manner.

Methods: This work was a retrospective analysis of the clinical data of 60 patients admitted to our hospital for unilateral radical thyroid cancer surgery between 01/2021 and 12/2022. The control group underwent COACAS (30 patients), and the experimental group underwent TAWISES (30 patients). The patients' operative time, intraoperative bleeding volume, 24-h postoperative pain index, drainage tube carrying time, hospitalization duration and complication rate were compared and analyzed. The patients were followed up for 3, 6 and 12 months postoperatively and evaluated based on numbness, muscular tightness, pain and other discomfort in the neck, as well as satisfaction with social adaptation and cosmetic incisions. The recurrence status was assessed for 1 year in both groups of patients. A questionnaire survey was conducted to assess patient acceptance of the two surgical approaches. The economic characteristics (cost-effectiveness and cost-utility) of the different approaches in our region were evaluated comprehensively.

Results: The length of the incision, drainage tube carrying time and hospitalization duration were greater in the experimental group than in the control group (P < 0.05). The differences in complication rate, intraoperative bleeding volume, 24-h postoperative pain index and recurrence rate were not statistically significant between the two groups (P > 0.05). Neck discomfort was greater in the control group, and the difference was statistically significant at the 3-month postoperative follow-up (P < 0.05). The differences at the 6- and 12-month postoperative follow-ups were not statistically significant (P > 0.05). However, mild discomfort was significantly more common in the experimental group (63.33% > 36.67%, 80% > 53.33%, P < 0.05). The experimental group had better social adaptability, greater total medical costs, and better overall patient medical satisfaction than did the control group (P < 0.05). The acceptance of TAWISL was greater than that of COACAS (P < 0.05).

Conclusion: Compared with COACLAS, TAWISES is safe and effective and better meets the cosmetic, psychological and social adaptation needs of patients. TAWISES is also more cost effective and can be better utilized for the population in our region, filling the gap in surgical modalities for thyroid cancer in in our region.

目的通过无充气单孔内镜手术(TAWISES)和传统开放式颈椎前路手术(COACAS)评估甲状腺癌根治术的卫生技术:本研究对我院2021年1月至2022年12月期间收治的60例单侧甲状腺癌根治术患者的临床资料进行了回顾性分析。对照组采用 COACAS(30 例),实验组采用 TAWISES(30 例)。对比分析了患者的手术时间、术中出血量、术后 24 小时疼痛指数、引流管携带时间、住院时间和并发症发生率。对患者进行术后 3 个月、6 个月和 12 个月的随访,并根据颈部麻木、肌肉紧绷、疼痛和其他不适感,以及对社会适应和切口美观的满意度进行评估。对两组患者的复发状况进行了为期一年的评估。还进行了问卷调查,以评估患者对两种手术方法的接受程度。对本地区不同方法的经济特征(成本效益和成本效用)进行了全面评估:实验组的切口长度、引流管携带时间和住院时间均大于对照组(P 0.05)。对照组颈部不适感更强,术后 3 个月随访时差异有统计学意义(P 0.05)。然而,轻度不适在实验组中明显更常见(63.33% > 36.67%,80% > 53.33%,P 结论:与 COACLAS 相比,TT-LAS 更能减轻颈部不适:与 COACLAS 相比,TAWISES 安全有效,能更好地满足患者的美容、心理和社会适应需求。TAWISES的成本效益也更高,可以更好地为本地区人群所用,填补了本地区甲状腺癌手术方式的空白。
{"title":"A controlled study of the hygienic technical evaluation of the transaxillary approach for inflation-free single-port lumpectomy versus conventional transcervical anterior open surgery in radical thyroid cancer resection.","authors":"Jie Chen, Bo Xu Bm, Chaojie Zhang Bm, Chengquan Ma, Tianwen Lu","doi":"10.1186/s12957-024-03445-y","DOIUrl":"https://doi.org/10.1186/s12957-024-03445-y","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate sanitary techniques for radical thyroid cancer surgery via the transaxillary approach without inflation single-port endoscopic surgery (TAWISES) and the conventional open anterior cervical approach (COACAS) in a controlled manner.</p><p><strong>Methods: </strong>This work was a retrospective analysis of the clinical data of 60 patients admitted to our hospital for unilateral radical thyroid cancer surgery between 01/2021 and 12/2022. The control group underwent COACAS (30 patients), and the experimental group underwent TAWISES (30 patients). The patients' operative time, intraoperative bleeding volume, 24-h postoperative pain index, drainage tube carrying time, hospitalization duration and complication rate were compared and analyzed. The patients were followed up for 3, 6 and 12 months postoperatively and evaluated based on numbness, muscular tightness, pain and other discomfort in the neck, as well as satisfaction with social adaptation and cosmetic incisions. The recurrence status was assessed for 1 year in both groups of patients. A questionnaire survey was conducted to assess patient acceptance of the two surgical approaches. The economic characteristics (cost-effectiveness and cost-utility) of the different approaches in our region were evaluated comprehensively.</p><p><strong>Results: </strong>The length of the incision, drainage tube carrying time and hospitalization duration were greater in the experimental group than in the control group (P < 0.05). The differences in complication rate, intraoperative bleeding volume, 24-h postoperative pain index and recurrence rate were not statistically significant between the two groups (P > 0.05). Neck discomfort was greater in the control group, and the difference was statistically significant at the 3-month postoperative follow-up (P < 0.05). The differences at the 6- and 12-month postoperative follow-ups were not statistically significant (P > 0.05). However, mild discomfort was significantly more common in the experimental group (63.33% > 36.67%, 80% > 53.33%, P < 0.05). The experimental group had better social adaptability, greater total medical costs, and better overall patient medical satisfaction than did the control group (P < 0.05). The acceptance of TAWISL was greater than that of COACAS (P < 0.05).</p><p><strong>Conclusion: </strong>Compared with COACLAS, TAWISES is safe and effective and better meets the cosmetic, psychological and social adaptation needs of patients. TAWISES is also more cost effective and can be better utilized for the population in our region, filling the gap in surgical modalities for thyroid cancer in in our region.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11210178/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141471162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intraoperative urinary tract resection and construction in CRS + HIPEC procedures: a single center retrospective analysis. CRS + HIPEC 手术中的术中尿路切除和构建:单中心回顾性分析。
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2024-06-26 DOI: 10.1186/s12957-024-03457-8
Zhong-He Ji, Yu-Bin Fu, Gang Liu, Yang Yu, Bing Li, Yan-Dong Su, Rui Yang, Xin-Li Liang, Yan Li

Introduction: The safety and efficacy of CRS + HIPEC combined with urinary tract resection and reconstruction are controversial. This study aims to summarize the clinicopathological features and to evaluate the safety and survival prognosis of CRS + HIPEC combined with urinary tract resection and reconstruction.

Methods: The patients who underwent urinary tract resection and reconstruction as part of CRS surgery were retrospectively selected from our disease-specific database for analysis. The clinicopathological characteristics, treatment-related variables, perioperative adverse events (AEs), and survival outcomes were studied using a descriptive approach and the K-M analysis with log-rank comparison.

Results: Forty-nine patients were enrolled. Perioperative serious AEs (SAEs) were observed in 11 patients (22.4%), with urinary SAEs occurring in 3 patients (6.1%). Additionally, there were 23 cases (46.8%) involving urinary adverse events (UAEs). The median overall survival (OS) in the entire cohort was 59.2 (95%CI: 42.1-76.4) months. The median OS of the UAE group and No-UAE group were 59.2 months (95%CI not reached), and 50.5 (95%CI: 11.5 to 89.6) months, respectively, with no significant difference (P = 0.475). Furthermore, there were no significant differences in OS based on the grade of UAEs or the number of UAEs (P = 0.562 and P = 0.622, respectively).

Conclusion: The combination of CRS + HIPEC with urinary tract resection and reconstruction is associated with a high incidence of Grade I-II UAEs, which do not have an impact on OS. The safety profile of this combined technique is acceptable. However, this is a retrospective single-center single-arm analysis, with limitations of generalizability and potential selection bias. The findings need high-level validation.

导言:CRS+HIPEC联合尿路切除和重建的安全性和有效性存在争议。本研究旨在总结 CRS + HIPEC 联合尿路切除和重建的临床病理特征,并评估其安全性和生存预后:方法:从我们的特定疾病数据库中回顾性选取在CRS手术中接受尿路切除和重建的患者进行分析。采用描述性方法和对数秩比较 K-M 分析法研究了临床病理特征、治疗相关变量、围手术期不良事件(AEs)和生存结果:结果:共纳入49例患者。11例患者(22.4%)发生了围手术期严重不良反应(SAE),其中3例患者(6.1%)发生了泌尿系统不良反应。此外,还有 23 例(46.8%)涉及泌尿系统不良事件(UAE)。整个组群的中位总生存期(OS)为59.2个月(95%CI:42.1-76.4)。UAE组和无UAE组的中位OS分别为59.2个月(95%CI未达)和50.5个月(95%CI:11.5至89.6),无显著差异(P = 0.475)。此外,根据UAE的等级或UAE的数量,OS无明显差异(P = 0.562和P = 0.622):结论:CRS+HIPEC联合尿路切除和重建术与I-II级UAE的高发生率有关,但对OS没有影响。这种联合技术的安全性是可以接受的。然而,这是一项回顾性的单中心单臂分析,在推广性和潜在选择偏倚方面存在局限性。研究结果需要高级别的验证。
{"title":"Intraoperative urinary tract resection and construction in CRS + HIPEC procedures: a single center retrospective analysis.","authors":"Zhong-He Ji, Yu-Bin Fu, Gang Liu, Yang Yu, Bing Li, Yan-Dong Su, Rui Yang, Xin-Li Liang, Yan Li","doi":"10.1186/s12957-024-03457-8","DOIUrl":"10.1186/s12957-024-03457-8","url":null,"abstract":"<p><strong>Introduction: </strong>The safety and efficacy of CRS + HIPEC combined with urinary tract resection and reconstruction are controversial. This study aims to summarize the clinicopathological features and to evaluate the safety and survival prognosis of CRS + HIPEC combined with urinary tract resection and reconstruction.</p><p><strong>Methods: </strong>The patients who underwent urinary tract resection and reconstruction as part of CRS surgery were retrospectively selected from our disease-specific database for analysis. The clinicopathological characteristics, treatment-related variables, perioperative adverse events (AEs), and survival outcomes were studied using a descriptive approach and the K-M analysis with log-rank comparison.</p><p><strong>Results: </strong>Forty-nine patients were enrolled. Perioperative serious AEs (SAEs) were observed in 11 patients (22.4%), with urinary SAEs occurring in 3 patients (6.1%). Additionally, there were 23 cases (46.8%) involving urinary adverse events (UAEs). The median overall survival (OS) in the entire cohort was 59.2 (95%CI: 42.1-76.4) months. The median OS of the UAE group and No-UAE group were 59.2 months (95%CI not reached), and 50.5 (95%CI: 11.5 to 89.6) months, respectively, with no significant difference (P = 0.475). Furthermore, there were no significant differences in OS based on the grade of UAEs or the number of UAEs (P = 0.562 and P = 0.622, respectively).</p><p><strong>Conclusion: </strong>The combination of CRS + HIPEC with urinary tract resection and reconstruction is associated with a high incidence of Grade I-II UAEs, which do not have an impact on OS. The safety profile of this combined technique is acceptable. However, this is a retrospective single-center single-arm analysis, with limitations of generalizability and potential selection bias. The findings need high-level validation.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11200841/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141459630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Locally advanced breast cancer patients should be cautious about the immediate breast reconstruction after mastectomy: a pooling analysis of safety and efficacy. 局部晚期乳腺癌患者应慎重考虑乳房切除术后立即进行乳房重建:安全性和有效性的汇总分析。
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2024-06-25 DOI: 10.1186/s12957-024-03444-z
Cheng-Yu Zeng, Yan-Yu Qiu, Jia-Yi Li, Jian-Hao Huang, Xue-Song Bai, Xian-Lin Han, Xiao-Dong He

Background: The purpose of this study was to compare safety and efficacy outcomes between immediate breast reconstruction (IBR) and mastectomy alone in locally advanced breast cancer patients.

Methods: We conducted a comprehensive literature search of PUBMED, EMBASE, and Cochrane databases. The primary outcomes evaluated were overall survival, disease-free survival, and local recurrence. The secondary outcome was the incidence of surgical complications. All data were analyzed using Review Manager 5.3.

Results: Sixteen studies, involving 15,364 participants were included in this meta-analysis. Pooled data demonstrated that patients underwent IBR were more likely to experience surgical complications than those underwent mastectomy alone (HR: 3.96, 95%CI [1.07,14.67], p = 0.04). No significant difference was found in overall survival (HR: 0.94, 95%CI [0.73,1.20], p = 0.62), disease-free survival (HR: 1.03, 95%CI [0.83,1.27], p = 0.81), or breast cancer specific survival (HR: 0.93, 95%CI [0.71,1.21], p = 0.57) between IBR group and Non-IBR group.

Conclusions: Our study demonstrates that IBR after mastectomy does not affect the overall survival and disease-free survival of locally advanced breast cancer patients. However, IBR brings with it a nonnegligible higher risk of complications and needs to be fully evaluated and carefully decided.

背景:本研究旨在比较局部晚期乳腺癌患者即刻乳房重建(IBR)和单纯乳房切除术的安全性和有效性:本研究旨在比较局部晚期乳腺癌患者即刻乳房重建术(IBR)和单纯乳房切除术的安全性和疗效:我们对 PUBMED、EMBASE 和 Cochrane 数据库进行了全面的文献检索。评估的主要结果是总生存率、无病生存率和局部复发率。次要结果是手术并发症的发生率。所有数据均使用 Review Manager 5.3 进行分析:本次荟萃分析共纳入16项研究,涉及15364名参与者。汇总数据显示,与单纯乳房切除术相比,接受 IBR 的患者更有可能出现手术并发症(HR:3.96,95%CI [1.07,14.67],P = 0.04)。在总生存率(HR:0.94,95%CI [0.73,1.20],P = 0.62)、无病生存率(HR:1.03,95%CI [0.83,1.27],P = 0.81)或乳腺癌特异性生存率(HR:0.93,95%CI [0.71,1.21],P = 0.57)方面,IBR 组与非 IBR 组无明显差异:我们的研究表明,乳房切除术后 IBR 不会影响局部晚期乳腺癌患者的总生存率和无病生存率。结论:我们的研究表明,乳房切除术后进行 IBR 不会影响局部晚期乳腺癌患者的总生存率和无病生存率,但 IBR 会带来不可忽视的较高并发症风险,因此需要进行全面评估并谨慎决定。
{"title":"Locally advanced breast cancer patients should be cautious about the immediate breast reconstruction after mastectomy: a pooling analysis of safety and efficacy.","authors":"Cheng-Yu Zeng, Yan-Yu Qiu, Jia-Yi Li, Jian-Hao Huang, Xue-Song Bai, Xian-Lin Han, Xiao-Dong He","doi":"10.1186/s12957-024-03444-z","DOIUrl":"10.1186/s12957-024-03444-z","url":null,"abstract":"<p><strong>Background: </strong>The purpose of this study was to compare safety and efficacy outcomes between immediate breast reconstruction (IBR) and mastectomy alone in locally advanced breast cancer patients.</p><p><strong>Methods: </strong>We conducted a comprehensive literature search of PUBMED, EMBASE, and Cochrane databases. The primary outcomes evaluated were overall survival, disease-free survival, and local recurrence. The secondary outcome was the incidence of surgical complications. All data were analyzed using Review Manager 5.3.</p><p><strong>Results: </strong>Sixteen studies, involving 15,364 participants were included in this meta-analysis. Pooled data demonstrated that patients underwent IBR were more likely to experience surgical complications than those underwent mastectomy alone (HR: 3.96, 95%CI [1.07,14.67], p = 0.04). No significant difference was found in overall survival (HR: 0.94, 95%CI [0.73,1.20], p = 0.62), disease-free survival (HR: 1.03, 95%CI [0.83,1.27], p = 0.81), or breast cancer specific survival (HR: 0.93, 95%CI [0.71,1.21], p = 0.57) between IBR group and Non-IBR group.</p><p><strong>Conclusions: </strong>Our study demonstrates that IBR after mastectomy does not affect the overall survival and disease-free survival of locally advanced breast cancer patients. However, IBR brings with it a nonnegligible higher risk of complications and needs to be fully evaluated and carefully decided.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11197261/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141451718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fertility-sparing re-treatment for endometrial cancer and atypical endometrial hyperplasia patients with progestin-resistance: a retrospective analysis of 61 cases. 对孕激素耐药的子宫内膜癌和非典型子宫内膜增生症患者进行保留生育力的再治疗:对 61 例病例的回顾性分析。
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2024-06-25 DOI: 10.1186/s12957-024-03439-w
Junyu Chen, Dongyan Cao

Objective: This study aimed to evaluate the oncological and reproductive outcomes of fertility-preserving re-treatment in progestin-resistant endometrial carcinoma (EC) and atypical endometrial hyperplasia (AEH) women who desire to maintain their fertility.

Methods: Our study included 61 progestin-resistant EC/AEH patients. These patients underwent treatment with gonadotropin-releasing hormone agonist (GnRHa) solely or a combination of GnRHa with levonorgestrel-releasing intrauterine system (LNG-IUD) or aromatase inhibitor (AI). Histological evaluations were performed every 3-4 months. Upon achieving complete remission (CR), we recommended maintenance treatments including LNG-IUD, cyclical oral contraceptives, or low-dose cyclic progestin until they began attempting conception. Regular follow-up was conducted for all patients. The chi-square method was utilized to compare oncological and fertility outcomes, while the Cox proportional hazards regression analysis helped identify risk factors for CR, recurrence, and pregnancy.

Results: Overall, 55 (90.2%) patients achieved CR, including 90.9% of AEH patients and 89.7% of EC patients. The median re-treatment time was 6 months (ranging from 3 to 12 months). The CR rate for GnRHa alone, GnRHa + LNG-IUD and GnRHa + AI were 80.0%, 91.7% and 93.3%, respectively. After a median follow-up period of 36 months (ranging from 3 to 96 months), 19 women (34.5%) experienced recurrence, 40.0% in AEH and 31.4% in EC patients, with the median recurrence time of 23 months (ranging from 6 to 77 months). Among the patients who achieved CR, 39 expressed a desire to conceive, 20 (51.3%) became pregnant, 11 (28.2%) had successfully deliveries, 1 (5.1%) was still pregnant, while 8 (20.5%) suffered miscarriages.

Conclusion: GnRHa-based fertility-sparing treatment exhibited promising oncological and reproductive outcomes for progestin-resistant patients. Future larger multi-institutional studies are necessary to confirm these findings.

研究目的本研究旨在评估对孕激素耐药的子宫内膜癌(EC)和非典型子宫内膜增生症(AEH)妇女进行保留生育力再治疗的肿瘤学和生殖结果:我们的研究包括61名孕激素耐药的EC/AEH患者。这些患者接受了单纯促性腺激素释放激素激动剂(GnRHa)治疗或 GnRHa 与左炔诺孕酮释放宫内节育器(LNG-IUD)或芳香化酶抑制剂(AI)联合治疗。每 3-4 个月进行一次组织学评估。在达到完全缓解(CR)后,我们建议进行维持治疗,包括LNG-宫内节育器、周期性口服避孕药或低剂量周期性孕激素,直到他们开始尝试受孕。我们对所有患者进行定期随访。采用卡方方法比较肿瘤和生育结果,而Cox比例危险回归分析则有助于确定CR、复发和妊娠的风险因素:总体而言,55 例(90.2%)患者达到了 CR,包括 90.9% 的 AEH 患者和 89.7% 的 EC 患者。中位再治疗时间为 6 个月(3 至 12 个月不等)。单用GnRHa、GnRHa+LNG-IUD和GnRHa+人工授精的CR率分别为80.0%、91.7%和93.3%。中位随访期为 36 个月(3 至 96 个月),19 名妇女(34.5%)复发,其中 40.0% 为 AEH 患者,31.4% 为 EC 患者,中位复发时间为 23 个月(6 至 77 个月)。在获得 CR 的患者中,39 人表达了怀孕意愿,20 人(51.3%)怀孕,11 人(28.2%)成功分娩,1 人(5.1%)仍在怀孕,8 人(20.5%)流产:结论:基于GnRHa的保胎治疗对孕激素耐药患者的肿瘤和生殖治疗效果很好。今后有必要开展更大规模的多机构研究,以证实这些发现。
{"title":"Fertility-sparing re-treatment for endometrial cancer and atypical endometrial hyperplasia patients with progestin-resistance: a retrospective analysis of 61 cases.","authors":"Junyu Chen, Dongyan Cao","doi":"10.1186/s12957-024-03439-w","DOIUrl":"10.1186/s12957-024-03439-w","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate the oncological and reproductive outcomes of fertility-preserving re-treatment in progestin-resistant endometrial carcinoma (EC) and atypical endometrial hyperplasia (AEH) women who desire to maintain their fertility.</p><p><strong>Methods: </strong>Our study included 61 progestin-resistant EC/AEH patients. These patients underwent treatment with gonadotropin-releasing hormone agonist (GnRHa) solely or a combination of GnRHa with levonorgestrel-releasing intrauterine system (LNG-IUD) or aromatase inhibitor (AI). Histological evaluations were performed every 3-4 months. Upon achieving complete remission (CR), we recommended maintenance treatments including LNG-IUD, cyclical oral contraceptives, or low-dose cyclic progestin until they began attempting conception. Regular follow-up was conducted for all patients. The chi-square method was utilized to compare oncological and fertility outcomes, while the Cox proportional hazards regression analysis helped identify risk factors for CR, recurrence, and pregnancy.</p><p><strong>Results: </strong>Overall, 55 (90.2%) patients achieved CR, including 90.9% of AEH patients and 89.7% of EC patients. The median re-treatment time was 6 months (ranging from 3 to 12 months). The CR rate for GnRHa alone, GnRHa + LNG-IUD and GnRHa + AI were 80.0%, 91.7% and 93.3%, respectively. After a median follow-up period of 36 months (ranging from 3 to 96 months), 19 women (34.5%) experienced recurrence, 40.0% in AEH and 31.4% in EC patients, with the median recurrence time of 23 months (ranging from 6 to 77 months). Among the patients who achieved CR, 39 expressed a desire to conceive, 20 (51.3%) became pregnant, 11 (28.2%) had successfully deliveries, 1 (5.1%) was still pregnant, while 8 (20.5%) suffered miscarriages.</p><p><strong>Conclusion: </strong>GnRHa-based fertility-sparing treatment exhibited promising oncological and reproductive outcomes for progestin-resistant patients. Future larger multi-institutional studies are necessary to confirm these findings.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11202344/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141451717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oncological outcomes of fertility-sparing surgery versus radical surgery in stage - epithelial ovarian cancer: a systematic review and meta-analysis. 分期上皮性卵巢癌保胎手术与根治手术的肿瘤学结果:系统回顾和荟萃分析。
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2024-06-25 DOI: 10.1186/s12957-024-03440-3
Ziting Guan, Changlin Zhang, Xinmei Lin, Jingwei Zhang, Tian Li, Jundong Li

Background: The oncological outcomes of fertility-sparing surgery (FSS) compared to radical surgery (RS) in patients with stage I epithelial ovarian cancer (EOC) remain a subject of debate. We evaluated the risk ratios (RRs) for outcomes in patients with stage I EOC who underwent FSS versus RS.

Methods: We conducted a systematic search of PubMed, Web of Science, and Embase for articles published up to November 29, 2023. Studies that did not involve surgical procedures or included pregnant patients were excluded. We calculated the RRs for disease-free survival, overall survival, and recurrence rate. The quality of the included studies was assessed using the Cochrane Risk of Bias in Nonrandomized Studies of Interventions (ROBINS-I) tool. The meta-analysis was registered on PROSPERO (CRD42024546460).

Results: From the 5,529 potentially relevant articles, we identified 83 articles for initial screening and included 12 articles in the final meta-analysis, encompassing 2,906 patients with epithelial ovarian cancer. There were no significant differences between the two groups in disease-free survival (RR [95% confidence interval {CI}], 0.90 [0.51, 1.58]; P = 0.71), overall survival (RR [95% CI], 0.74 [0.53, 1.03]; P = 0.07), and recurrence rate (RR [95% CI], 1.10 [0.69, 1.76]; P = 0.68). In sensitivity analyses, the significant difference was observed only for overall survival (before exclusion: RR [95% CI], 0.74 [0.53-1.03], P = 0.07; after exclusion: RR [95% CI], 0.70 [0.50-0.99]; P = 0.04).

Conclusions: This is the first and only individual patient data meta-analysis comparing disease-free survival, overall survival, and recurrence rate of patients with early-stage epithelial ovarian cancer undergoing FSS and RS. FSS was associated with similar disease-free survival and risk of recurrence as RS. We hypothesized that the decreased overall survival in the FSS group could not be attributed to distant metastases from epithelial ovarian cancer.

背景:在I期上皮性卵巢癌(EOC)患者中,保胎手术(FSS)与根治手术(RS)的肿瘤治疗效果仍存在争议。我们评估了接受 FSS 与 RS 手术的 I 期 EOC 患者预后的风险比 (RR):我们在 PubMed、Web of Science 和 Embase 中对截至 2023 年 11 月 29 日发表的文章进行了系统检索。排除了不涉及外科手术或包含妊娠患者的研究。我们计算了无病生存率、总生存率和复发率。纳入研究的质量采用 Cochrane 非随机干预研究偏倚风险(ROBINS-I)工具进行评估。该荟萃分析已在 PROSPERO(CRD42024546460)上注册:从5529篇可能相关的文章中,我们初步筛选出83篇,并在最终的荟萃分析中纳入了12篇,涉及2906名上皮性卵巢癌患者。两组患者的无病生存率(RR [95% 置信区间 {CI}],0.90 [0.51, 1.58];P = 0.71)、总生存率(RR [95% CI],0.74 [0.53, 1.03];P = 0.07)和复发率(RR [95% CI],1.10 [0.69, 1.76];P = 0.68)无明显差异。在敏感性分析中,仅在总生存率方面观察到显著差异(排除前:RR [95% CI], 1.10 [0.69, 1.76];P = 0.68):RR[95%CI],0.74 [0.53-1.03],P = 0.07;排除后:RR[95%CI],0.70 [0.50-0.99];P = 0.04):这是第一项也是唯一一项比较接受FSS和RS治疗的早期上皮性卵巢癌患者的无病生存期、总生存期和复发率的患者个体数据荟萃分析。FSS的无病生存期和复发风险与RS相似。我们假设,FSS 组患者总生存率的下降不能归因于上皮性卵巢癌的远处转移。
{"title":"Oncological outcomes of fertility-sparing surgery versus radical surgery in stage - epithelial ovarian cancer: a systematic review and meta-analysis.","authors":"Ziting Guan, Changlin Zhang, Xinmei Lin, Jingwei Zhang, Tian Li, Jundong Li","doi":"10.1186/s12957-024-03440-3","DOIUrl":"10.1186/s12957-024-03440-3","url":null,"abstract":"<p><strong>Background: </strong>The oncological outcomes of fertility-sparing surgery (FSS) compared to radical surgery (RS) in patients with stage I epithelial ovarian cancer (EOC) remain a subject of debate. We evaluated the risk ratios (RRs) for outcomes in patients with stage I EOC who underwent FSS versus RS.</p><p><strong>Methods: </strong>We conducted a systematic search of PubMed, Web of Science, and Embase for articles published up to November 29, 2023. Studies that did not involve surgical procedures or included pregnant patients were excluded. We calculated the RRs for disease-free survival, overall survival, and recurrence rate. The quality of the included studies was assessed using the Cochrane Risk of Bias in Nonrandomized Studies of Interventions (ROBINS-I) tool. The meta-analysis was registered on PROSPERO (CRD42024546460).</p><p><strong>Results: </strong>From the 5,529 potentially relevant articles, we identified 83 articles for initial screening and included 12 articles in the final meta-analysis, encompassing 2,906 patients with epithelial ovarian cancer. There were no significant differences between the two groups in disease-free survival (RR [95% confidence interval {CI}], 0.90 [0.51, 1.58]; P = 0.71), overall survival (RR [95% CI], 0.74 [0.53, 1.03]; P = 0.07), and recurrence rate (RR [95% CI], 1.10 [0.69, 1.76]; P = 0.68). In sensitivity analyses, the significant difference was observed only for overall survival (before exclusion: RR [95% CI], 0.74 [0.53-1.03], P = 0.07; after exclusion: RR [95% CI], 0.70 [0.50-0.99]; P = 0.04).</p><p><strong>Conclusions: </strong>This is the first and only individual patient data meta-analysis comparing disease-free survival, overall survival, and recurrence rate of patients with early-stage epithelial ovarian cancer undergoing FSS and RS. FSS was associated with similar disease-free survival and risk of recurrence as RS. We hypothesized that the decreased overall survival in the FSS group could not be attributed to distant metastases from epithelial ovarian cancer.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11201297/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141451719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tumor-associated characteristics and immune dysregulation in nasopharyngeal carcinoma under the regulation of m7G-related tumor microenvironment cells. m7G 相关肿瘤微环境细胞调控下鼻咽癌的肿瘤相关特征和免疫失调。
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2024-06-25 DOI: 10.1186/s12957-024-03441-2
Zhen Long, Xiaochen Li, Wenmin Deng, Yan Tan, Jie Liu

Background: Nasopharyngeal carcinoma (NPC) is a type of malignant tumor with high morbidity. Aberrant levels of N7-methylguanosine (m7G) are closely associated with tumor progression. However, the characteristics of the tumor microenvironment (TME) in NPC associated with m7G modification remain unclear.

Methods: A total of 68,795 single cells from single-cell RNA sequencing data derived from 11 NPC tumor samples and 3 nasopharyngeal lymphatic hyperplasia (NLH) samples were clustered using a nonnegative matrix factorization algorithm according to 61 m7G RNA modification regulators.

Results: The m7G regulators were found differential expression in the TME cells of NPC, and most m7G-related immune cell clusters in NPC tissues had a higher abundance compared to non-NPC tissues. Specifically, m7G scores in the CD4+ and CD8+ T cell clusters were significantly lower in NPC than in NLH. T cell clusters differentially expressed immune co-stimulators and co-inhibitors. Macrophage clusters differentially expressed EIF4A1, and high EIF4A1 expression was associated with poor survival in patients with head and neck squamous carcinoma. EIF4A1 was upregulated in NPC tissues compared to the non-NPC tissues and mainly expressed in CD86+ macrophages. Moreover, B cell clusters exhibited tumor biological characteristics under the regulation of m7G-related genes in NPC. The fibroblast clusters interacted with the above immune cell clusters and enriched tumor biological pathways, such as FGER2 signaling pathway. Importantly, there were correlations and interactions through various ligand-receptor links among epithelial cells and m7G-related TME cell clusters.

Conclusion: Our study revealed tumor-associated characteristics and immune dysregulation in the NPC microenvironment under the regulation of m7G-related TME cells. These results demonstrated the underlying regulatory roles of m7G in NPC.

背景:鼻咽癌是一种发病率很高的恶性肿瘤。N7-甲基鸟苷(m7G)水平异常与肿瘤进展密切相关。然而,与 m7G 修饰相关的鼻咽癌肿瘤微环境(TME)的特征仍不清楚:方法:根据61个m7G RNA修饰调节因子,采用非负矩阵因式分解算法对来自11个鼻咽癌肿瘤样本和3个鼻咽淋巴增生(NLH)样本的单细胞RNA测序数据中的68795个单细胞进行聚类:结果:在鼻咽癌的TME细胞中发现了m7G调节因子的差异表达,与非鼻咽癌组织相比,鼻咽癌组织中大多数m7G相关免疫细胞群的丰度更高。具体而言,鼻咽癌中CD4+和CD8+ T细胞群的m7G得分明显低于非鼻咽癌组织。T细胞集群对免疫共刺激物和共抑制物的表达存在差异。巨噬细胞集群不同程度地表达了EIF4A1,EIF4A1的高表达与头颈部鳞状细胞癌患者的不良生存率有关。与非鼻咽癌组织相比,EIF4A1在鼻咽癌组织中上调,且主要在CD86+巨噬细胞中表达。此外,在 m7G 相关基因的调控下,鼻咽癌中的 B 细胞集群表现出肿瘤生物学特征。成纤维细胞集群与上述免疫细胞集群相互作用,并丰富了肿瘤生物学通路,如 FGER2 信号通路。重要的是,上皮细胞与 m7G 相关的 TME 细胞集群之间通过各种配体-受体联系存在相关性和相互作用:我们的研究揭示了在 m7G 相关 TME 细胞调控下鼻咽癌微环境中的肿瘤相关特征和免疫失调。这些结果证明了 m7G 在鼻咽癌中的潜在调控作用。
{"title":"Tumor-associated characteristics and immune dysregulation in nasopharyngeal carcinoma under the regulation of m7G-related tumor microenvironment cells.","authors":"Zhen Long, Xiaochen Li, Wenmin Deng, Yan Tan, Jie Liu","doi":"10.1186/s12957-024-03441-2","DOIUrl":"10.1186/s12957-024-03441-2","url":null,"abstract":"<p><strong>Background: </strong>Nasopharyngeal carcinoma (NPC) is a type of malignant tumor with high morbidity. Aberrant levels of N7-methylguanosine (m7G) are closely associated with tumor progression. However, the characteristics of the tumor microenvironment (TME) in NPC associated with m7G modification remain unclear.</p><p><strong>Methods: </strong>A total of 68,795 single cells from single-cell RNA sequencing data derived from 11 NPC tumor samples and 3 nasopharyngeal lymphatic hyperplasia (NLH) samples were clustered using a nonnegative matrix factorization algorithm according to 61 m7G RNA modification regulators.</p><p><strong>Results: </strong>The m7G regulators were found differential expression in the TME cells of NPC, and most m7G-related immune cell clusters in NPC tissues had a higher abundance compared to non-NPC tissues. Specifically, m7G scores in the CD4<sup>+</sup> and CD8<sup>+</sup> T cell clusters were significantly lower in NPC than in NLH. T cell clusters differentially expressed immune co-stimulators and co-inhibitors. Macrophage clusters differentially expressed EIF4A1, and high EIF4A1 expression was associated with poor survival in patients with head and neck squamous carcinoma. EIF4A1 was upregulated in NPC tissues compared to the non-NPC tissues and mainly expressed in CD86<sup>+</sup> macrophages. Moreover, B cell clusters exhibited tumor biological characteristics under the regulation of m7G-related genes in NPC. The fibroblast clusters interacted with the above immune cell clusters and enriched tumor biological pathways, such as FGER2 signaling pathway. Importantly, there were correlations and interactions through various ligand-receptor links among epithelial cells and m7G-related TME cell clusters.</p><p><strong>Conclusion: </strong>Our study revealed tumor-associated characteristics and immune dysregulation in the NPC microenvironment under the regulation of m7G-related TME cells. These results demonstrated the underlying regulatory roles of m7G in NPC.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11202337/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141451721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quantitative assessment of the associations between DNA repair gene XRCC3 Thr241Met polymorphism and pancreatic cancer. DNA修复基因XRCC3 Thr241Met多态性与胰腺癌关系的定量评估
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2024-06-25 DOI: 10.1186/s12957-024-03450-1
Wenjing Wu, Sen Xu, Lingzhi Chen, Chaomin Ji, Tianyu Liang, Mangmang He

Background: Prior research exploring the correlation between the XRCC3 Thr241Met polymorphism and the susceptibility to pancreatic cancer has yielded conflicting outcomes. To date, there has been a notable absence of studies examining this polymorphism. The primary aim of the current investigation is to elucidate the potential role of the XRCC3 Thr241Met polymorphism as a risk factor in the development of pancreatic cancer.

Methods: The comprehensive literature search was meticulously conducted across primary databases, including PubMed, Embase, and CNKI (China National Knowledge Infrastructure), spanning from the inception of each database through January 2024. To synthesize the data, a meta-analysis was performed using either a fixed or random-effects model, as appropriate, to calculate the odds ratios (ORs) and their corresponding 95% confidence intervals (CIs).

Results: The analysis revealed significant associations between the XRCC3 Thr241Met polymorphism and an increased risk of pancreatic cancer. This was evidenced through various genetic model comparisons: allele contrast (T vs. C: OR = 0.77, 95% CI = 0.70-0.86, P < 0.001), homozygote comparison (TT vs. CC: OR = 0.71, 95% CI = 0.58-0.88, P = 0.001), heterozygote comparison (TC vs. CC: OR = 0.67, 95% CI = 0.52-0.87, P = 0.003), and a dominant genetic model (TT/TC vs. CC: OR = 0.68, 95% CI = 0.57-0.81, P < 0.001). Additionally, subgroup analyses based on ethnicity disclosed that these associations were particularly pronounced in the Caucasian population, with all genetic models showing significance (P < 0.05).

Conclusions: The XRCC3 Thr241Met polymorphism has been identified as contributing to a reduced risk of pancreatic cancer in the Caucasian population. This finding underscores the need for further research to validate and expand upon our conclusions, emphasizing the urgency for continued investigations in this domain.

背景:之前对 XRCC3 Thr241Met 多态性与胰腺癌易感性之间相关性的研究结果相互矛盾。迄今为止,明显缺乏对这一多态性的研究。本次调查的主要目的是阐明 XRCC3 Thr241Met 多态性作为胰腺癌发病风险因素的潜在作用:在PubMed、Embase和CNKI(中国国家知识基础设施)等主要数据库中进行了细致全面的文献检索,时间跨度从各数据库建立之初至2024年1月。为了对数据进行综合,我们酌情使用固定效应或随机效应模型进行了荟萃分析,计算出了几率比(ORs)及其相应的95%置信区间(CIs):分析结果显示,XRCC3 Thr241Met 多态性与胰腺癌风险增加之间存在明显关联。通过各种遗传模型比较可以证明这一点:等位基因对比(T 与 C:OR = 0.77,95% CI = 0.70-0.86,P 结论:XRCC3 Thr241Met 多态性与胰腺癌风险增加之间存在显著关联:在高加索人群中,XRCC3 Thr241Met 多态性已被确定为导致胰腺癌风险降低的因素。这一发现强调了进一步研究的必要性,以验证和扩展我们的结论,并强调了在这一领域继续开展调查的紧迫性。
{"title":"Quantitative assessment of the associations between DNA repair gene XRCC3 Thr241Met polymorphism and pancreatic cancer.","authors":"Wenjing Wu, Sen Xu, Lingzhi Chen, Chaomin Ji, Tianyu Liang, Mangmang He","doi":"10.1186/s12957-024-03450-1","DOIUrl":"10.1186/s12957-024-03450-1","url":null,"abstract":"<p><strong>Background: </strong>Prior research exploring the correlation between the XRCC3 Thr241Met polymorphism and the susceptibility to pancreatic cancer has yielded conflicting outcomes. To date, there has been a notable absence of studies examining this polymorphism. The primary aim of the current investigation is to elucidate the potential role of the XRCC3 Thr241Met polymorphism as a risk factor in the development of pancreatic cancer.</p><p><strong>Methods: </strong>The comprehensive literature search was meticulously conducted across primary databases, including PubMed, Embase, and CNKI (China National Knowledge Infrastructure), spanning from the inception of each database through January 2024. To synthesize the data, a meta-analysis was performed using either a fixed or random-effects model, as appropriate, to calculate the odds ratios (ORs) and their corresponding 95% confidence intervals (CIs).</p><p><strong>Results: </strong>The analysis revealed significant associations between the XRCC3 Thr241Met polymorphism and an increased risk of pancreatic cancer. This was evidenced through various genetic model comparisons: allele contrast (T vs. C: OR = 0.77, 95% CI = 0.70-0.86, P < 0.001), homozygote comparison (TT vs. CC: OR = 0.71, 95% CI = 0.58-0.88, P = 0.001), heterozygote comparison (TC vs. CC: OR = 0.67, 95% CI = 0.52-0.87, P = 0.003), and a dominant genetic model (TT/TC vs. CC: OR = 0.68, 95% CI = 0.57-0.81, P < 0.001). Additionally, subgroup analyses based on ethnicity disclosed that these associations were particularly pronounced in the Caucasian population, with all genetic models showing significance (P < 0.05).</p><p><strong>Conclusions: </strong>The XRCC3 Thr241Met polymorphism has been identified as contributing to a reduced risk of pancreatic cancer in the Caucasian population. This finding underscores the need for further research to validate and expand upon our conclusions, emphasizing the urgency for continued investigations in this domain.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11202253/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141451720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Which factors are associated with adverse prognosis in multiple myeloma patients after surgery? - preliminary establishment and validation of the nomogram. 哪些因素与多发性骨髓瘤患者术后的不良预后有关?- 提名图的初步建立和验证。
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2024-06-25 DOI: 10.1186/s12957-024-03453-y
Jun-Peng Liu, Zi-Yu Xu, Yue Wu, Xiang-Jun Shi, Ming Shi, Meng Li, Xin-Ru Du, Xing-Chen Yao

Background: To investigate the prognosis of patients with Multiple Myeloma (MM) after surgery, analyze the risk factors leading to adverse postoperative outcomes, and establish a nomogram.

Methods: Clinical data from 154 patients with MM who underwent surgery at our institution between 2007 and 2019 were retrospectively analyzed. Assessing and comparing patients' pain levels, quality of life, and functional status before and after surgery (P < 0.05) were considered statistically significant. The Kaplan-Meier survival curve was used to estimate the median survival time. Adverse postoperative outcomes were defined as worsened symptoms, lesion recurrence, complication grade ≥ 2, or a postoperative survival period < 1 year. Logistic regression analysis was used to determine the prognostic factors. Based on the logistic regression results, a nomogram predictive model was developed and calibrated.

Results: Postoperative pain was significantly alleviated in patients with MM, and there were significant improvements in the quality of life and functional status (P < 0.05). The median postoperative survival was 41 months. Forty-nine patients (31.8%) experienced adverse postoperative outcomes. Multivariate logistic regression analysis identified patient age, duration of MM, International Staging System, preoperative Karnofsky Performance Status, and Hb < 90 g/L as independent factors influencing patient prognosis. Based on these results, a nomogram was constructed, with a C-index of 0.812. The calibration curve demonstrated similarity between the predicted and actual survival curves. Decision curve analysis favored the predictive value of the model at high-risk thresholds from 10% to-69%.

Conclusion: This study developed a nomogram risk prediction model to assist in providing quantifiable assessment indicators for preoperative evaluation of surgical risk.

背景:研究多发性骨髓瘤(MM)患者术后的预后,分析导致术后不良预后的风险因素,并建立预后提名图:研究多发性骨髓瘤(MM)患者术后的预后,分析导致术后不良预后的风险因素,并建立提名图:方法:回顾性分析2007年至2019年期间在我院接受手术治疗的154例多发性骨髓瘤患者的临床数据。评估并比较患者术前和术后的疼痛程度、生活质量和功能状态(P 结果:术后疼痛明显减轻的患者,术前疼痛程度明显减轻;术后疼痛明显减轻的患者,术前疼痛程度明显减轻:MM患者术后疼痛明显减轻,生活质量和功能状态也有显著改善(P 结论:MM患者术后疼痛明显减轻,生活质量和功能状态也有显著改善:本研究建立了一个提名图风险预测模型,为术前评估手术风险提供可量化的评估指标。
{"title":"Which factors are associated with adverse prognosis in multiple myeloma patients after surgery? - preliminary establishment and validation of the nomogram.","authors":"Jun-Peng Liu, Zi-Yu Xu, Yue Wu, Xiang-Jun Shi, Ming Shi, Meng Li, Xin-Ru Du, Xing-Chen Yao","doi":"10.1186/s12957-024-03453-y","DOIUrl":"10.1186/s12957-024-03453-y","url":null,"abstract":"<p><strong>Background: </strong>To investigate the prognosis of patients with Multiple Myeloma (MM) after surgery, analyze the risk factors leading to adverse postoperative outcomes, and establish a nomogram.</p><p><strong>Methods: </strong>Clinical data from 154 patients with MM who underwent surgery at our institution between 2007 and 2019 were retrospectively analyzed. Assessing and comparing patients' pain levels, quality of life, and functional status before and after surgery (P < 0.05) were considered statistically significant. The Kaplan-Meier survival curve was used to estimate the median survival time. Adverse postoperative outcomes were defined as worsened symptoms, lesion recurrence, complication grade ≥ 2, or a postoperative survival period < 1 year. Logistic regression analysis was used to determine the prognostic factors. Based on the logistic regression results, a nomogram predictive model was developed and calibrated.</p><p><strong>Results: </strong>Postoperative pain was significantly alleviated in patients with MM, and there were significant improvements in the quality of life and functional status (P < 0.05). The median postoperative survival was 41 months. Forty-nine patients (31.8%) experienced adverse postoperative outcomes. Multivariate logistic regression analysis identified patient age, duration of MM, International Staging System, preoperative Karnofsky Performance Status, and Hb < 90 g/L as independent factors influencing patient prognosis. Based on these results, a nomogram was constructed, with a C-index of 0.812. The calibration curve demonstrated similarity between the predicted and actual survival curves. Decision curve analysis favored the predictive value of the model at high-risk thresholds from 10% to-69%.</p><p><strong>Conclusion: </strong>This study developed a nomogram risk prediction model to assist in providing quantifiable assessment indicators for preoperative evaluation of surgical risk.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11202362/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141451722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Application of microwave ablation assisted degradation therapy in surgical treatment of intramedullary chondrosarcoma of extremities. 微波消融辅助降解疗法在四肢髓内软骨肉瘤手术治疗中的应用。
IF 2.5 3区 医学 Q1 Medicine Pub Date : 2024-06-24 DOI: 10.1186/s12957-024-03443-0
Xinzhu Qiu, Hongbo He, Can Zhang, Yupeng Liu, Hao Zeng, Qing Liu

Aim: Clinical diagnosis and surgical treatment of chondrosarcoma (CS) are continuously improving. The purpose of our study is to evaluate the effectiveness of microwave ablation (MWA) assisted degradation therapy in the surgical treatment of intramedullary chondrosarcoma of the extremities, to provide a new reference and research basis for the surgical treatment of CS.

Methods: We recruited 36 patients with intramedullary CS who underwent MWA assisted extended curettage. Preoperative patient demographics and clinical data were recorded. Surgery was independently assisted by a medical team. Patients were followed up strictly and evaluated for oncological prognosis, radiological results, limb joint function, pain, and complications.

Results: We included 15 men and 21 women (mean age: 43.5 ± 10.1). The average length of the lesion was 8.1 ± 2.5 cm. Based on preoperative radiographic, clinical manifestations, and pathological results of puncture biopsy, 28 patients were preliminarily diagnosed with CS-grade I and eight patients with CS-grade II. No recurrence or metastasis occurred in the postoperative follow-up. The average Musculoskeletal Tumor Society score was 28.8 ± 1.0, significantly better than presurgery. Secondary shoulder periarthritis and abduction dysfunction occurred in early postoperative stage CS of the proximal humerus in some, but returned to normal after rehabilitation exercise. Secondary bursitis occurred at the knee joint in some due to the internal fixation device used in treatment; however, secondary osteoarthritis and avascular necrosis of the femoral head were not observed. Overall, oncological and functional prognoses were satisfactory.

Conclusions: The application of MWA assisted degradation therapy in intramedullary CS can achieve satisfactory oncology and functional prognosis, providing a new option for the limited treatment of CS.

目的:软骨肉瘤(CS)的临床诊断和手术治疗正在不断改进。我们的研究旨在评估微波消融(MWA)辅助降解疗法在四肢髓内软骨肉瘤手术治疗中的效果,为CS的手术治疗提供新的参考和研究依据:方法:我们招募了36名接受MWA辅助扩大刮除术的髓内CS患者。术前记录了患者的人口统计学和临床数据。手术由医疗团队独立协助。对患者进行严格随访,评估肿瘤预后、放射学结果、肢体关节功能、疼痛和并发症:患者中有 15 名男性和 21 名女性(平均年龄为 43.5±10.1 岁)。病变平均长度为 8.1 ± 2.5 厘米。根据术前影像学、临床表现和穿刺活检的病理结果,28 名患者被初步诊断为 CS I 级,8 名患者为 CS II 级。术后随访未发现复发或转移。肌肉骨骼肿瘤协会平均评分为(28.8±1.0)分,明显优于术前。部分患者在肱骨近端CS期术后早期出现继发性肩关节周围炎和外展臂功能障碍,但在康复锻炼后恢复正常。由于在治疗中使用了内固定装置,一些患者的膝关节出现了继发性滑囊炎;但未观察到继发性骨关节炎和股骨头血管性坏死。总体而言,肿瘤和功能预后令人满意:结论:在髓内CS中应用MWA辅助降解疗法可获得满意的肿瘤学和功能性预后,为CS的有限治疗提供了一种新的选择。
{"title":"Application of microwave ablation assisted degradation therapy in surgical treatment of intramedullary chondrosarcoma of extremities.","authors":"Xinzhu Qiu, Hongbo He, Can Zhang, Yupeng Liu, Hao Zeng, Qing Liu","doi":"10.1186/s12957-024-03443-0","DOIUrl":"10.1186/s12957-024-03443-0","url":null,"abstract":"<p><strong>Aim: </strong>Clinical diagnosis and surgical treatment of chondrosarcoma (CS) are continuously improving. The purpose of our study is to evaluate the effectiveness of microwave ablation (MWA) assisted degradation therapy in the surgical treatment of intramedullary chondrosarcoma of the extremities, to provide a new reference and research basis for the surgical treatment of CS.</p><p><strong>Methods: </strong>We recruited 36 patients with intramedullary CS who underwent MWA assisted extended curettage. Preoperative patient demographics and clinical data were recorded. Surgery was independently assisted by a medical team. Patients were followed up strictly and evaluated for oncological prognosis, radiological results, limb joint function, pain, and complications.</p><p><strong>Results: </strong>We included 15 men and 21 women (mean age: 43.5 ± 10.1). The average length of the lesion was 8.1 ± 2.5 cm. Based on preoperative radiographic, clinical manifestations, and pathological results of puncture biopsy, 28 patients were preliminarily diagnosed with CS-grade I and eight patients with CS-grade II. No recurrence or metastasis occurred in the postoperative follow-up. The average Musculoskeletal Tumor Society score was 28.8 ± 1.0, significantly better than presurgery. Secondary shoulder periarthritis and abduction dysfunction occurred in early postoperative stage CS of the proximal humerus in some, but returned to normal after rehabilitation exercise. Secondary bursitis occurred at the knee joint in some due to the internal fixation device used in treatment; however, secondary osteoarthritis and avascular necrosis of the femoral head were not observed. Overall, oncological and functional prognoses were satisfactory.</p><p><strong>Conclusions: </strong>The application of MWA assisted degradation therapy in intramedullary CS can achieve satisfactory oncology and functional prognosis, providing a new option for the limited treatment of CS.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11194926/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141447116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
World Journal of Surgical Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1